{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T03:55:49Z","timestamp":1781322949007,"version":"3.54.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jaad.2016.01.052","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T13:15:13Z","timestamp":1456665313000},"page":"203-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["End points in dermatologic clinical trials: A review for clinicians"],"prefix":"10.1016","volume":"75","author":[{"given":"Erin X.","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Kirsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Eaglstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.01.052_bib1","series-title":"The FDA for doctors","author":"Eaglstein","year":"2014"},{"key":"10.1016\/j.jaad.2016.01.052_bib2","unstructured":"Centers for Disease Control and Prevention. National Ambulatory Medical Care survey-factsheet dermatology, 2009. Available from: URL: http:\/\/www.cdc.gov\/nchs\/data\/ahcd\/NAMCS_Factsheet_DERM_2009.pdf. Accessed May 1, 2014."},{"key":"10.1016\/j.jaad.2016.01.052_bib3","unstructured":"Centers for Disease Control and Prevention. National Ambulatory Medical Care survey-factsheet dermatology, 2010. Available from: URL: http:\/\/www.cdc.gov\/nchs\/data\/ahcd\/NAMCS_2010_factsheet_dermatology.pdf. Accessed May 1, 2014."},{"key":"10.1016\/j.jaad.2016.01.052_bib4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaad.2006.05.048","article-title":"The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology","volume":"55","author":"Bickers","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.01.052_bib5","unstructured":"Sullivan EJ; US Food and Drug Administration. Clinical trial endpoints. Available from: URL: http:\/\/www.fda.gov\/downloads\/Training\/ClinicalInvestigatorTrainingCourse\/UCM283378.pdf. Accessed September 8, 2015."},{"key":"10.1016\/j.jaad.2016.01.052_bib6","unstructured":"US Food and Drug Administration. Fast track, breakthrough therapy, accelerated approval and priority review, 2015. Available from: URL: http:\/\/www.fda.gov\/forpatients\/approvals\/fast\/ucm20041766.htm. Accessed October 5, 2015."},{"issue":"3","key":"10.1016\/j.jaad.2016.01.052_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(14)70007-5","article-title":"Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomized controlled trials","volume":"15","author":"Flaherty","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2016.01.052_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jaad.2016.01.052_bib9","unstructured":"US Food and Drug Administration. Romidepsin, 2013. Available from: URL: http:\/\/www.fda.gov\/aboutfda\/centersoffices\/officeofmedicalproductsandtobacco\/cder\/ucm189466.htm. Accessed October 20, 2015."},{"issue":"11","key":"10.1016\/j.jaad.2016.01.052_bib10","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2016.01.052_bib11","unstructured":"National Cancer Institute. FDA approval for denileukin diftitox, 2013. Available from: URL: http:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/fda-denileukindiftitox. Accessed October 15, 2015."},{"issue":"18","key":"10.1016\/j.jaad.2016.01.052_bib12","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2016.01.052_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.01.052_bib14","unstructured":"US Food and Drug Administration. Trametinib and dabrafenib, 2014. Available from: URL: http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm381451.htm. Accessed September 8, 2015."},{"key":"10.1016\/j.jaad.2016.01.052_bib15","unstructured":"US Food and Drug Administration. FDA approves first-of-its-kind product for the treatment of melanoma, 2015. Available from: URL: http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm469571.htm. Accessed November 1, 2015."},{"issue":"1","key":"10.1016\/j.jaad.2016.01.052_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10543400802541693","article-title":"Some controversial multiple testing problems in regulatory applications","volume":"19","author":"Hung","year":"2009","journal-title":"J Biopharm Stat"},{"issue":"7597","key":"10.1016\/j.jaad.2016.01.052_bib17","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/bmj.39136.682083.AE","article-title":"Problems with use of composite end points in cardiovascular trials: systematic review of randomized controlled trials","volume":"334","author":"Ferreira-Gonzalez","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2016.01.052_bib18","unstructured":"US Food and Drug Administration. Draft guidance on imiquimod, 2011. Available from: URL: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM281452.pdf. Accessed May 8, 2014."},{"key":"10.1016\/j.jaad.2016.01.052_bib19","unstructured":"US Food and Drug Administration. Draft guidance on fluorouracil, 2011. Available from: URL: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM249240.pdf. Accessed May 8, 2014."},{"issue":"5","key":"10.1016\/j.jaad.2016.01.052_bib20","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2016.01.052_bib21","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1365-4632.2012.05776.x","article-title":"Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis","volume":"52","author":"Wolf","year":"2013","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2016.01.052_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/120347540500900501","article-title":"Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies","volume":"9","author":"Gupta","year":"2005","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.jaad.2016.01.052_bib23","first-page":"128","article-title":"Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study","volume":"7","author":"Huyke","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.jaad.2016.01.052_bib24","first-page":"156","article-title":"Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp","volume":"5","author":"Smith","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2016.01.052_bib25","unstructured":"US Food and Drug Administration. Guidance for industry acne vulgaris: developing drugs for treatment, 2005. Available from: URL: http:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/UCM071292.pdf. Accessed May 8, 2014."},{"key":"10.1016\/j.jaad.2016.01.052_bib26","unstructured":"CenterWatch. Veltin (clindamycin phosphate and tretinoin). Available from: URL: https:\/\/www.centerwatch.com\/drug-information\/fda-approved-drugs\/drug\/1107\/veltin-clindamycin-phosphate-and-tretinoin. Accessed August 20, 2015."},{"issue":"2","key":"10.1016\/j.jaad.2016.01.052_bib27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1067\/mjd.2002.120912","article-title":"Acne therapy: a methodologic review","volume":"47","author":"Lehmann","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2016.01.052_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-4362.1980.tb01983.x","article-title":"Clinical trials in dermatology, part 3: measuring responses to treatment","volume":"19","author":"Allen","year":"1980","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2016.01.052_bib29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0190-9622(96)90680-5","article-title":"A multirater validation study to assess the reliability of acne lesion counting","volume":"35","author":"Lucky","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2016.01.052_bib30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0190-9622(08)80076-X","article-title":"Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990","volume":"24","author":"Pochi","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.01.052_bib31","unstructured":"US Food and Drug Administration. Background package for open session on clinical development for the pediatric use of systemic products in the treatment of atopic dermatitis inadequately responsive to topical therapies, 2015. Available from: URL: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/DermatologicandOphthalmicDrugsAdvisoryCommittee\/UCM436605.pdf. Accessed October 1, 2015."},{"key":"10.1016\/j.jaad.2016.01.052_bib32","unstructured":"US Food and Drug Administration. Draft guidance on tacrolimus, 2013. Available from: URL: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm296988.pdf. Accessed May 8, 2014."},{"key":"10.1016\/j.jaad.2016.01.052_bib33","unstructured":"CenterWatch. Desonate (desonide). Available from: URL: https:\/\/www.centerwatch.com\/drug-information\/fda-approved-drugs\/drug\/937\/desonate-desonide. Accessed January 10, 2016."},{"issue":"6","key":"10.1016\/j.jaad.2016.01.052_bib34","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1046\/j.1523-1747.2003.12251.x","article-title":"Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring?","volume":"120","author":"Charman","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.01.052_bib35","unstructured":"US Food and Drug Administration. Guidance for industry, patient-reported outcome measures: use in medical product development to support labeling claims, 2009. Available from: URL: http:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/UCM193282.pdf. Accessed September 8, 2015."},{"issue":"3","key":"10.1016\/j.jaad.2016.01.052_bib36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3816\/CBC.2004.n.025","article-title":"Quality of life in women with advanced breast cancer treated with docetaxel","volume":"5","author":"Twelves","year":"2004","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2016.01.052_bib37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/annonc\/mdh087","article-title":"Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel","volume":"15","author":"Gridelli","year":"2004","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.jaad.2016.01.052_bib38","doi-asserted-by":"crossref","first-page":"vi51","DOI":"10.1093\/annonc\/mdp255","article-title":"A systematic review of health-related quality of life in cutaneous melanoma","volume":"20","author":"Cornish","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2016.01.052_bib39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1477-7525-7-58","article-title":"Rasch analysis of the Multiple Sclerosis Impact Scale MSIS-29","volume":"7","author":"Ramp","year":"2009","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.jaad.2016.01.052_bib40","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1378\/chest.129.4.925","article-title":"Brief questionnaires for patient-reported outcomes in asthma: validation and usefulness in a primary care setting","volume":"129","author":"Ehrs","year":"2006","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jaad.2016.01.052_bib41","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2133.2006.07185.x","article-title":"A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases","volume":"155","author":"Beattie","year":"2006","journal-title":"Br J Dermatol"},{"issue":"3 Pt 1","key":"10.1016\/j.jaad.2016.01.052_bib42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0190-9622(94)70213-6","article-title":"Atopic dermatitis: triggering factors","volume":"31","author":"Morren","year":"1994","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2016.01.052_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clindermatol.2011.11.004","article-title":"Psychosomatic factors in pruritus","volume":"31","author":"Tey","year":"2013","journal-title":"Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2016.01.052_bib44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1440-0960.1998.tb01477.x","article-title":"Factors that may affect the response of onychomycosis to oral antifungal therapy","volume":"39","author":"Gupta","year":"1998","journal-title":"Australasian Journal of Dermatology"},{"issue":"3","key":"10.1016\/j.jaad.2016.01.052_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-4362.2002.01436.x","article-title":"Atopic dermatitis is associated with a decrement in health-related quality of life","volume":"41","author":"Kiebert","year":"2002","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2016.01.052_bib46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11882-001-0041-3","article-title":"Effects of allergic dermatosis on health-related quality of life","volume":"1","author":"Anderson","year":"2001","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaad.2016.01.052_bib47","unstructured":"US Food and Drug Administration. Medical devices and clinical trial design for the treatment or improvement in the appearance of fungally-infected nails, 2015. Available from: URL: http:\/\/www.fda.gov\/downloads\/medicaldevices\/deviceregulationandguidance\/guidancedocuments\/ucm431312.pdf. Accessed September 1, 2015."},{"issue":"4","key":"10.1016\/j.jaad.2016.01.052_bib48","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","article-title":"Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies","volume":"68","author":"Elewski","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2016.01.052_bib49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00019053-200220010-00003","article-title":"Onychomycosis: health-related quality of life considerations","volume":"20","author":"Shaw","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jaad.2016.01.052_bib50","unstructured":"US Food and Drug Administration. Chronic cutaneous ulcer and burn wounds \u2014 developing products for treatment, 2006. Available from: URL: http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm071324.pdf. Accessed May 8, 2014."},{"issue":"6","key":"10.1016\/j.jaad.2016.01.052_bib51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.12968\/jowc.2010.19.6.48471","article-title":"European Wound Management Association Patient Outcome Group. Outcomes in controlled and comparative studies on non-healing wounds: recommendations to improve the quality of evidence in wound management","volume":"19","author":"Gottrup","year":"2010","journal-title":"J Wound Care"},{"issue":"3","key":"10.1016\/j.jaad.2016.01.052_bib52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1524-475X.1994.20304.x","article-title":"Regulatory concerns in the development of topical recombinant ophthalmic and cutaneous wound healing biologics","volume":"2","author":"Stromberg","year":"1994","journal-title":"Wound Repair Regen"},{"issue":"2","key":"10.1016\/j.jaad.2016.01.052_bib53","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1524-475X.1999.00090.x","article-title":"Original articles: ease of wound closure as an endpoint of treatment efficacy","volume":"7","author":"Robson","year":"1999","journal-title":"Wound Repair Regen"},{"issue":"5","key":"10.1016\/j.jaad.2016.01.052_bib54","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2337\/diacare.21.5.822","article-title":"Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study","volume":"21","author":"Wieman","year":"1998","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jaad.2016.01.052_bib55","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1524-475x.2001.00347.x","article-title":"Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers","volume":"9","author":"Robson","year":"2001","journal-title":"Wound Repair Regen"},{"issue":"3","key":"10.1016\/j.jaad.2016.01.052_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00000637-199209000-00001","article-title":"Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers","volume":"29","author":"Robson","year":"1992","journal-title":"Ann Plast Surg"},{"issue":"3","key":"10.1016\/j.jaad.2016.01.052_bib57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1524-475X.1999.00141.x","article-title":"Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study","volume":"7","author":"Rees","year":"1999","journal-title":"Wound Repair Regen"},{"issue":"6","key":"10.1016\/j.jaad.2016.01.052_bib58","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1046\/j.1523-1747.2002.19629.x","article-title":"Surrogate endpoints for the treatment of venous leg ulcers","volume":"119","author":"Gelfand","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2016.01.052_bib59","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/archderm.134.12.1571","article-title":"Efficacy and prognostic value of simple wound measurements","volume":"134","author":"Kantor","year":"1998","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2016.01.052_bib60","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archderm.1997.03890460053006","article-title":"Initial rate of healing predicts complete healing of venous ulcers","volume":"133","author":"Tallman","year":"1997","journal-title":"Arch Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2016.01.052_bib61","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.2337\/diab.40.10.1305","article-title":"Chronology and determinants of tissue repair in diabetic lower-extremity ulcers","volume":"40","author":"Pecoraro","year":"1991","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.jaad.2016.01.052_bib62","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.semcdb.2012.09.014","article-title":"The FDA and designing clinical trials for chronic cutaneous ulcers","volume":"23","author":"Maderal","year":"2012","journal-title":"Seminars in cell & developmental biology"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2016.01.052_bib63","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0001-7310(09)73172-2","article-title":"Challenges encountered in dermatologic drug development","volume":"100","author":"Eaglstein","year":"2009","journal-title":"Actas dermo-sifiliograficas"},{"key":"10.1016\/j.jaad.2016.01.052_bib64","unstructured":"US Food and Drug Administration. Upper facial lines: developing botulinum toxin drug products, 2014. Available from: URL: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM407983.pdf. Accessed February 20, 2016."},{"issue":"11","key":"10.1016\/j.jaad.2016.01.052_bib65","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/jamadermatol.2015.2881","article-title":"Assessment of botulinum toxin aesthetic outcomes: clinical study vs real-world practice","volume":"151","author":"Glogau","year":"2015","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216013177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216013177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:39:38Z","timestamp":1759271978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216013177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0190962216013177"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.01.052","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"End points in dermatologic clinical trials: A review for clinicians","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.01.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}